Gut microbiota affects brain development and behavior
Preclinical and clinical evidence reviewed indicates that gut microbiota modulates neural development and behavior, with a preliminary favorable signal for fecal microbiota transplantation (FMT) in ASD severity, but no quantifiable effect size with 95% CI due to the narrative nature of the review.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Hippocampal neurogenesis (GF models) | C | ▲ Favorable | Increased dorsal hippocampal neurogenesis in GF mice vs. controls; reversed by recolonization; no IC 95% | 1 |
| Prefrontal cortex myelination (GF models) | C | ▲ Favorable | Upregulation of myelination genes in GF mice prefrontal cortex; reversed by conventional microbiota recolonization; no IC 95% | 1 |
| Microglial development (GF/antibiotic models) | C | ▲ Favorable | Immature microglial phenotype in GF/antibiotic mice; normalized by SCFA supplementation for 4 weeks; no IC 95% | 2 |
| Gut microbiota composition in ASD (meta-analyses) | B | — Insufficient | Three meta-analyses (9–18 studies; 356–642 ASD vs. 356–404 controls) show contradictory taxa differences across studies; no consistent taxon identified; no pooled OR/RR with IC 95% | 3 |
| ASD severity with probiotics (clinical trials) | C | — Insufficient | Inconsistent results across 13 trials (n=8–131); some RDBPC show no significant behavioral change (Arnold 2019, n=13); others show ↓ ATEC/CARS in open-label; no pooled effect size with IC 95% | 13 |
| ASD severity with FMT (2-year follow-up) | C | ▲ Favorable | Kang 2019 (n=18, open-label): severe ASD 83%→17% at 2y; 44% below diagnostic cutoff; no IC 95% or formal statistical test reported | 2 |
| Gastrointestinal symptoms in ASD with FMT | C | ▲ Favorable | Kang 2017 (n=18) and Li 2021 (n=40): improvement in GI symptoms reported; no quantified absolute/relative effect with IC 95% | 2 |
Context
The microbiota-gut-brain axis is a plausible mechanism for neurodevelopmental disorders. ASD has a high prevalence of gastrointestinal comorbidities and documented dysbiosis. Microbiota-targeted interventions represent an investigational therapeutic target in this population.
What the study showed
Germ-free mice show increased dorsal hippocampal neurogenesis, upregulation of myelination genes in the prefrontal cortex, and altered synaptic plasticity genes, all reversed by microbial recolonization. In clinical FMT studies (n=18, Kang 2017/2019), 83% of participants had severe ASD at baseline; at 2-year follow-up, only 17% remained in that category and 44% fell below the diagnostic cutoff. Probiotic studies showed inconsistent results across trials with no standardizable effect. No referenced meta-analysis identified a specific bacterial taxon consistently associated with ASD.
How it was done
Narrative review published in 2023 in a Korean pediatric journal (Clin Exp Pediatr). Synthesizes preclinical data (GF mouse models), three meta-analyses on gut microbiota in ASD (9–18 studies each), and 16 clinical trials of microbiota interventions in children with ASD. No PRISMA protocol or prospective registration declared.
Effect magnitude
No pooled effect size calculated in the review. The most cited FMT study (Kang 2019, n=18, open-label) reports reduction of severe ASD cases from 83% to 17% at 2 years, without formal 95% CI or statistical testing reported in the review. Data insufficient to derive RR or OR.
Limitations
Narrative review without PRISMA methodology and no formal risk of bias assessment (RoB 2 or ROBINS-I not applied). Most cited clinical trials are open-label with small samples (n=8–131) and inadequate blinding. Heterogeneity of interventions, outcome scales, and populations prevents direct comparison. The three referenced meta-analyses report contradictory findings on the same taxa. Publication bias not assessed.
In clinical practice
Evidence is insufficient to recommend FMT or probiotics as standard treatment for ASD. Clinicians should inform caregivers that data are preliminary, mostly from open-label studies with small samples. Microbiota interventions in children with ASD should occur within approved research protocols.
What is still missing
Adequately blinded RCTs with larger samples and extended follow-up are needed to establish efficacy and safety of FMT in ASD. Standardization of sequencing methods and inclusion criteria is a prerequisite for conclusive meta-analyses.